Osteoperiosteal Revision (TOPIC/AOPT/Periosteal Patch)

→ Instead of taking a cartilage-bone plug from your knee (OATS) or a donor talus (allograft), osteoperiosteal grafting uses bone + the periosteum (living bone-lining tissue) from your iliac crest (hip bone) or distal tibia. The periosteum acts as a biological cover that can regenerate cartilage-like tissue. No knee donor site, no cadaver tissue.

Why This Category Matters

Osteoperiosteal procedures directly address lesions that are not just surface cartilage problems but involve cartilage + subchondral bone + cystic/reactive bone. They avoid knee donor-site morbidity (the main OATS concern) and donor tissue availability issues (the main allograft concern).

TOPIC: 5-Year Prospective Results (2024)

The 2024 prospective report on Transplantation of Osteoperiosteal Iliac-Crest graft (TOPIC) showed excellent mid-term outcomes [145]:

• No major complications reported
• A 2025 prospective lateral-TOPIC series showed pain improving from 5 to 1 at 2 years, 100% graft consolidation, no complications, no donor-site morbidity, and no reoperations in the first 7 patients

AOPT vs AOCT Head-to-Head (2025)

The strongest recent comparative signal: a 2025 study of 65 vs 65 patients comparing autologous osteoperiosteal transplantation (AOPT) to autologous osteochondral transplantation (AOCT/OATS) [146]:

• Both approaches produced very similar postoperative AOFAS, VAS, MRI, and second-look arthroscopy results
• Knee donor-site morbidity: 0% with AOPT vs 9.23% with AOCT
• Large cystic lesions defined as cyst diameter >10 mm
• Excluded moderate/severe OA and malalignment

Added August 6, 2026 — a randomized trial on exactly this lesion phenotype, which this page did not hold

→ The comparison above is a matched retrospective study. There is now a genuine randomized trial asking the same question, restricted to large cystic lesions of the medial talus — which is the specific description of this ankle.

Yang S, Hu F, Shao Q, Zhang Z — “Autologous Osteoperiosteal Transplantation Versus Autologous Osteochondral Transplantation for Large Cystic Osteochondral Lesions of the Medial Talus: 2-Year Results From a Prospective Randomized Controlled Trial”, American Journal of Sports Medicine 2025 [383]:

• Randomized controlled trial, Level 2 evidence, n=70, enrolled May 2018 – July 2022
• Restricted to large cystic OLTs, cyst diameter >8 mm, medial talus — the closest match to this lesion in the entire literature
• Outcomes: VAS, AOFAS and ankle activity score at 3, 6, 12 and 24 months, plus MOCART on MRI and second-look arthroscopic ICRS scoring; donor-site morbidity recorded across the full 24 months
• The stated hypothesis was that AOPT would be “associated with noninferior efficacy and less donor site morbidity” than AOCT
• Recorded honestly: the PubMed abstract truncates before the outcome numbers, so what this trial actually found is not stated here. The result direction is unknown from the abstract alone and the full text has not been read. This entry establishes that the trial exists and covers his phenotype — it does not report its answer

→ Worth flagging to whichever surgeon he sees: this is Level 2 evidence on large cystic medial talar lesions, and it is the strongest study design that has ever been applied to this exact problem. Getting the full text is a genuine to-do.

Also added: the same Amsterdam group's formal “Concise 5-Year Follow-up of a Previous Report” for TOPIC in JBJS 2026 [387], together with its invited critical commentary, Usuelli FG & D'Ambrosi R, “TOPIC at 5 Years: Promising Pain Relief, Unanswered Questions About the Relationship Between Structural Changes and Symptoms” [388]. Neither has an abstract in PubMed — the JBJS record carries only the level-of-evidence line — so no numbers are quoted from either. The commentary's title is the finding available without the text: independent reviewers think TOPIC's pain benefit is established and its structural claims are not. Checked and found correct: the 2024 five-year report cited above [145] was re-verified this week and is genuinely a five-year report (Hollander, Dahmen, Stufkens, Kerkhoffs; n=29) with the numbers as stated — a suggestion that this page had mislabelled two-year data as five-year was investigated and is wrong.

Added August 12, 2026 — the osteoperiosteal graft just lost a head-to-head, to a rib

→ This page compares osteoperiosteal grafts against osteochondral plugs from the knee. A new study from Shanghai asks a different question: what if the graft came from the patient's own rib cartilage instead? In their series, the rib graft won.

Wang J et al. (Ma X, Shi Z senior authors) — “Autologous costochondral transplantation in the treatment of Hepple V osteochondral lesions of talus: a retrospective analysis”, J Orthop Traumatol, published August 12, 2026, open access [411]:

• 53 ankles with Hepple V (cystic) OLT: 27 autologous costochondral transplantation (ACT) vs 26 osteoperiosteal transplantation (OPT), Shanghai Sixth People’s Hospital, 2020–2022, Level IV retrospective
• Both arms improved on FAAM-ADL, FAAM-Sports and EQ VAS — but every postoperative timepoint favoured the ACT group
• The MRI signal is the interesting part: ACT’s MOCART 2.0 scores kept improving between 12 months and final follow-up; OPT’s did not — consistent with a graft that carries actual cartilage continuing to mature, where periosteum-derived repair tissue plateaus
• Complications minimal in both arms (hardware removal 11.1% vs 7.7%, one wound-healing problem, no non-unions)

Read with both hands on the caveats: retrospective and single-center, so selection bias is unconstrained; the ACT arm almost certainly overlaps the same hospital’s 27-patient rib-cartilage cohort already on topic 23 [176], so this is the technique’s home institution grading its own work; and outcome magnitudes are not extracted here, only directions. It does not overturn the Yang RCT question above — that trial compares OPT against osteochondral plugs [383]. What it adds is a third graft source to the comparison set for cystic Hepple V lesions, with simultaneous cartilage-plus-bone and no knee donor site — and a specific question for any surgeon proposing an osteoperiosteal graft: why periosteum-derived repair tissue rather than a graft that brings cartilage with it?

Added August 26, 2026 — the bone-graft family gets its first pooled numbers, and a first-line claim for large lesions

→ A systematic review pooled eleven studies of treating talar lesions with bone graft alone — the family this page’s procedures belong to. Function scores went from about 56 to 89, pain from 6.5 to 1.7, and the pooled complication rate was under 4%. The authors go further than anyone has: for lesions bigger than 1.5 cm², they propose bone grafting should be considered first-line.

Everything on this page has been single series — the 42-patient AOPT cohort, the five-year TOPIC results, the 30-patient periosteal-patch study. A PRISMA systematic review and meta-analysis in the Journal of the American Podiatric Medical Association (Law, Koh, Seow — the senior author from the NYU/foot-ankle SR group) now pools the category: eleven studies of autologous bone grafting for osteochondral lesions of the talus [442]. Pooled outcomes: AOFAS 56.0 ± 10.1 → 88.7 ± 5.7; VAS pain 6.5 → 1.7; overall pooled complication rate 3.82% (CI 0.05–10.92), with one DVT the only debilitating complication reported across the studies. Their position statement is the notable part: autologous bone grafting “should be considered as the first line of treatment for lesion sizes >150 mm²” — presented as an alternative to osteochondral transplantation for exactly the large-lesion territory where OATS pays donor-site costs and allograft pays availability and chondrocyte-viability costs.

Discounts, which are substantial. The eleven pooled studies are the same retrospective, mostly single-center series this page already carries individually — pooling them tightens the estimate but inherits every selection bias, and [439] on topic 9 is this week’s reminder of how flattering retrospective cartilage-repair numbers run. Follow-ups are short (“longer follow-ups are desirable” is the authors’ own closing line), the bone-grafting techniques pooled are heterogeneous (iliac crest, distal tibia, with and without periosteum), and a first-line proposal in a review is an argument, not a guideline. What it is worth here: this ankle’s lesion, with its cystic subchondral component, sits in the size-and-depth territory the review is talking about, and the category’s pooled complication profile — under 4%, no graft-specific catastrophes — is now on record as the safest-looking of the resurfacing families. A question worth carrying into any revision consult: whether the bone-plus-periosteum version of this family fits before the allograft rung is spent.

Added September 17, 2026 — the AOPT developers attack their operation’s two weakest points with a printed jig — and expose how often the standard version lets the cyst come back

→ The Beijing group that developed the bone-plus-periosteum transplant this page is about has started planning the operation on a computer first: they rehearse the surgery on a 3D model of the patient’s ankle, then print a custom cutting guide that steers both the malleolar cut and the socket for the graft. In 32 patients with exactly this lesion type — large, cystic, medial — the guided version meant less pain, an easier recovery at the ankle-cut site, surgery about 45 minutes shorter, and a cyst returning in 1 patient in 13 instead of nearly 1 in 2. That last number cuts both ways: the guided results are encouraging, and the 47% cyst-recurrence rate in the conventional arm is the most honest look yet at the standard operation’s weakest point.

The standing objections to AOPT on this page have been operative complexity, osteotomy morbidity, and — via topic 27 — the question of whether the cyst comes back. A new Foot & Ankle International cohort from Peking University Third Hospital, the technique’s home institution, addresses all three at once [480]: medial cystic OLTs over 100 mm² and/or 8 mm deep, 13 patients with computer-simulated planning and patient-specific 3D-printed guide plates navigating the osteotomy and the bone socket, versus 19 with conventional AOPT. The customized group: lower pain (VAS 2.0 vs 3.0, P=.004), better daily function (FAAM-ADL +5.75, P<.001), 0.74 hours less operative time (P<.001), and cyst recurrence of 7.7% versus 47.4% (P=.024). Osteotomy-site morbidity fell from 42.1% to 7.7% and just missed significance (P=.050).

Read it with its limits: Level III, retrospective, 32 patients, not randomized — and the developers grading their own refinement, at the same single center whose cohorts already populate this site’s BMS pages, so the independence discount compounds. Sport scores and MRI repair-tissue grades showed no difference with these numbers. And a patient cannot order a simulation-plus-jig workflow off a menu; outside a few centers this remains a description of where the technique is going, not an available choice. What it changes here is still real: the phenotype enrolled is this ankle’s phenotype to the millimeter — medial, cystic, ~90 mm² — and the paper simultaneously strengthens the case that AOPT’s execution problems are addressable and quantifies, in its own control arm, how often the standard version leaves the cyst question open. Both halves belong in any consult where AOPT is on the table; and the question “would the osteotomy and socket be planned on the CT?” now has a literature anchor — one more argument for the CT that is already this site’s standing action item.

Periosteal Patch Approach (2025)

A separate 2025 study of 30 patients with large (>1.5 cm²) or recurrent OLTs used cancellous bone graft from the distal tibia plus a periosteal cover:

Return to Sport After TOPIC (2026)

The 2026 return-to-sport study showed strong recovery but a notable reoperation pattern [147]:

• About 1 in 3 patients had additional surgery, mostly for hardware or impingement rather than graft failure

Limitations

• Evidence base is still mostly single-center and short-to-mid-term
• The big AOPT-vs-AOCT study is around 12 months, lateral TOPIC data are 2 years, main TOPIC report is 5 years
• No 2024-2026 series found specifically on failed talar allograft revised by TOPIC/AOPT — relevance to Raymond's case is persuasive but indirect

Critical for Raymond: This is the most important new conversation because it directly addresses bone loss and the surface defect without forcing a choice between another donor talus or a knee harvest. The 0% vs 9.23% knee morbidity difference against comparable outcomes is the strongest single data point.